Alex Seelenberger joined Aurus Asset Management in 2008 to lead the Venture Capital Life Science Division. Aurus BIOS, launched in 2010, has made 9 investments, with a focus on early stage development companies in biotechnology, specialty pharma, diagnostics and medical devices, agbio and industrial biotech.Previous to Aurus, Alex worked at Athelera LLC, a merger and acquisitions firm in New York, where he focused on M&As across several industries within Latin America. Additionally, he was a consultant for the Boston Consulting Group focusing primarily in pharmaceutical industry, financial services, and mining projects.Alex holds an MBA – Baker Scholar – from Harvard University and a Commercial Engineering degree from Universidad de Chile.